Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO

Government and Regulatory

China's National Healthcare Security Administration announced that 70 drugs have been added to the list of drugs eligible for insurance reimbursement after biopharmas agreed to price cuts that averaged 61% (see story). Two new products from western companies, anemia treatment roxadustat from AstraZeneca and lung cancer therapy alecensa from Roche, are now covered by China's insurance plan. And China's domestic PD-1 therapy for Hodgkin’s lymphoma, Tyvyt, co-developed by Suzhou's Innovent and Eli Lilly, was also added, the first PD-1 on the list, even though China has five approved PD-1/PD-L1 products, including two from the US. By including Tyvyt in the reimbursement list, the NHSA may have given Tyvyt a big boost in early market positioning.

1 2 3 4
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.